Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment.
Rolfo C, Isambert N, Italiano A, Molife LR, Schellens JHM, Blay JY, Decaens T, Kristeleit R, Rosmorduc O, Demlova R, Lee MA, Ravaud A, Kopeckova K, Learoyd M, Bannister W, Locker G, de Vos-Geelen J.
Rolfo C, et al.
Br J Clin Pharmacol. 2020 Sep;86(9):1807-1818. doi: 10.1111/bcp.14283. Epub 2020 Apr 5.
Br J Clin Pharmacol. 2020.
PMID: 32227355
Free PMC article.
For patients with mild or moderate hepatic impairment, no new safety signals were detected. CONCLUSION: Patients with MiHI or MoHI had no clinically significant changes in exposure to olaparib compared with patients with NHF. ...No olaparib tablet or capsule dose reduction …
For patients with mild or moderate hepatic impairment, no new safety signals were detected. CONCLUSION: Patients with MiHI or MoHI ha …